1 study found for:    19451549 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Treatment of Metastatic Cancer That Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3 HLA-A*01-restricted TCR-Gene Engineered Lymphocytes and Aldesleukin
Conditions: Metastatic Cancer;   Metastatic Melanoma
Interventions: Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Anti-MAGE-A3 HLAA* 01-restricted TCR

Indicates status has not been verified in more than two years